


REMARKS/ARGUMENTS

With this amendment, Applicants respectfully request cancellation of Original Figures 1 and 3. Applicants also respectfully request entry of amendments to the specification to reflect the cancellation of original Figures 1 and 3 and renumbering of original Figures 2, 4, and 5; as amended Figures 1, 2, and 3, respectively. Applicants assert that the results depicted in original Figure 1 are described in Example III, page 65 in the paragraph beginning at line 19. Applicants also assert that the results depicted in original Figure 3 are described in Example IV, page 66 in the paragraph beginning at line 4. Thus, even after cancellation of original Figures 1 and 3, the information depicted therein is disclosed in the specification.

CONCLUSION

Entry of this amendment is respectfully urged since it merely cures a formal defect in original Figures 1 and 3 and does not touch the merits.

Respectfully submitted,



Beth L. Kelly
Reg. No. 51,868



TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
Attachments
BLK:blk
60207732 v1



~~Canceled~~


~~Figure 1~~

Specific Polyclonal antibodies for ING2 and ING1 by ELISA





~~1~~
Figure 2






Canceled
~~Figure 3~~

ING2 inhibits cell growth of HCT116 cell line by Colony Formation Assay.

We constructed ING2 and anti-ING2 mammalian expression vectors (CMV promoter, Neomycin resistant). We transfected them into human colon cancer cell line, HCT116. Transfected cells were selected by Neomycin and ING2 inhibitory effect for cell growth was determined by Colony Formation Assay.

HCT116: human, hereditary non-polyposis colon cancer cell line, wt p53



pcDNA3

pcDNA3-Anti-ING2

pcDNA3-ING2

Colony number

+++


+++

+




Figure ²/₄

p33ING2 protein was induced by topoisomerase II inhibitor, etoposide.
(p33ING1 was not induced.)





RKO
 pcDNA3.1 (control)



Sync Wizard Model


Date acquired: 20-Jul-99
 File: RKO P 4-1ug 2days
 Source: RKO P 4-1ug 2days
 Case: PATIENT ID
 Analysis type: Manual analysis
 Prep: Unknown

G0G1: 43.13 % Mean: 92.50
 CV: 5.03 %
 G2M: 32.50 % Mean: 175.58
 G2/G1: 1.91
 S-Phase: 24.38 % Mean: 134.93

Compartment 1: 24.38 %

Modeled Events: 7650
 RCS: 5.831

RKO
 p33ING1



Sync Wizard Model


Date acquired: 20-Jul-99
 File: RKO ING1 4-1ug 2days
 Source: RKO ING1 4-1ug 2days
 Case: PATIENT ID
 Analysis type: Manual analysis
 Prep: Unknown

G0G1: 67.14 % Mean: 106.56
 CV: 5.60 %
 G2M: 21.67 % Mean: 198.20
 G2/G1: 1.86
 S-Phase: 11.18 % Mean: 152.86

Compartment 1: 11.18 %

Modeled Events: 3732
 RCS: 4.762

RKO
 p33ING2



Sync Wizard Model

Date acquired: 20-Jul-99
 File: RKO ING2 4-1ug 2days
 Source: RKO ING2 4-1ug 2days
 Case: PATIENT ID
 Analysis type: Manual analysis
 Prep: Unknown

G0G1: 71.18 % Mean: 105.68
 CV: 4.77 %
 G2M: 19.97 % Mean: 198.00
 G2/G1: 1.67
 S-Phase: 8.85 % Mean: 152.28

Compartment 1: 8.85 %

Modeled Events: 10047
 RCS: 3.209